- Home
- SHIP vs IVA Comparison
SHIP vs IVA Comparison
Compare SHIP & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHIP
- IVA
- Stock Information
- Founded
- SHIP 2008
- IVA 2011
- Country
- SHIP Greece
- IVA France
- Employees
- SHIP N/A
- IVA N/A
- Industry
- SHIP Marine Transportation
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- SHIP Consumer Discretionary
- IVA Health Care
- Exchange
- SHIP Nasdaq
- IVA Nasdaq
- Market Cap
- SHIP 143.6M
- IVA 127.0M
- IPO Year
- SHIP 2007
- IVA 2020
- Fundamental
- Price
- SHIP $7.01
- IVA $2.84
- Analyst Decision
- SHIP Strong Buy
- IVA Strong Buy
- Analyst Count
- SHIP 3
- IVA 4
- Target Price
- SHIP $12.00
- IVA $13.25
- AVG Volume (30 Days)
- SHIP 230.0K
- IVA 10.9K
- Earning Date
- SHIP 03-14-2025
- IVA 03-26-2025
- Dividend Yield
- SHIP 10.84%
- IVA N/A
- EPS Growth
- SHIP N/A
- IVA N/A
- EPS
- SHIP 2.36
- IVA N/A
- Revenue
- SHIP $165,210,000.00
- IVA $20,652,523.00
- Revenue This Year
- SHIP $52.91
- IVA N/A
- Revenue Next Year
- SHIP N/A
- IVA $197.46
- P/E Ratio
- SHIP $2.97
- IVA N/A
- Revenue Growth
- SHIP 66.32
- IVA N/A
- 52 Week Low
- SHIP $6.55
- IVA $1.53
- 52 Week High
- SHIP $13.19
- IVA $4.50
- Technical
- Relative Strength Index (RSI)
- SHIP 49.51
- IVA 69.74
- Support Level
- SHIP $6.56
- IVA $2.58
- Resistance Level
- SHIP $7.42
- IVA $2.80
- Average True Range (ATR)
- SHIP 0.27
- IVA 0.15
- MACD
- SHIP 0.06
- IVA 0.04
- Stochastic Oscillator
- SHIP 48.39
- IVA 81.31
About SHIP Seanergy Maritime Holdings Corp.
Seanergy Maritime Holdings Corp is an international shipping company that provides marine dry bulk transportation services through the ownership and operation of dry bulk vessels. It generates a majority of its revenue from the vessels. The company fleet of vessels includes Fellowship, Championship, Partnership, Knightship, Lordship, Gloriuship, Leadership, Geniuship, Premiership, and Squireship among others.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.